Details for Patent: 11,491,169
✉ Email this page to a colleague
Which drugs does patent 11,491,169 protect, and when does it expire?
Patent 11,491,169 protects VEKLURY and is included in one NDA.
Protection for VEKLURY has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has eight patent family members in eight countries.
Drugs Protected by US Patent 11,491,169
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | VEKLURY | remdesivir | POWDER;INTRAVENOUS | 214787-001 | Oct 22, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Gilead Sciences Inc | VEKLURY | remdesivir | SOLUTION;INTRAVENOUS | 214787-002 | Oct 22, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,491,169
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2021281351 | ⤷ Sign Up | |||
| Canada | 3179226 | ⤷ Sign Up | |||
| China | 115666570 | ⤷ Sign Up | |||
| European Patent Office | 4157272 | ⤷ Sign Up | |||
| Japan | 2023528810 | ⤷ Sign Up | |||
| South Korea | 20230018473 | ⤷ Sign Up | |||
| Taiwan | 202203941 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
